Abstract In October 2022, the FDA Oncology Center of Excellence hosted an educational
symposium entitled,“Considering Functional Outcomes as Efficacy Endpoints in Pediatric …

Abstract Background and Aims The expanding use of chemotherapy in curative cancer
treatment has simultaneously resulted in a substantial and growing cohort of cancer …

Progress in the development of effective chemotherapy is producing a growing population of
patients with acute and chronic painful chemotherapy-induced peripheral neuropathy …

Background: Vincristine is a vital constituent of chemotherapeutic regimens. Vincristine-
induced neuropathy is a challenging adverse effect that impacts quality of life and treatment …

Background Chemotherapy is an important treatment for children with cancer, and
chemotherapy-induced pain is an important role in affecting patients' quality of life. In our …

Aims: Vincristine (VCR), an antineoplastic drug, induces peripheral neuropathy
characterized by nerve damage, limiting its use and reducing the quality of life of patients …

Many anti-cancer drugs, such as taxanes, platinum compounds, vinca alkaloids, and
proteasome inhibitors, can cause chemotherapy-induced peripheral neuropathy (CIPN) …

Aims Gastrointestinal paresthesia and dysmotility are common side effects of vincristine
(VCR) chemotherapy, which have become one of the factors for dose reduction, therapy …

Simple Summary Improving experimental conditions in preclinical animal studies is
essential. Automated digital ventilated cages offer the advantage of continuous monitoring of …

Objectives: The study aims to assess the proportion and magnitude of chemotherapy-
induced peripheral neuropathy (CIPN) and other common complications reported in children …